Thyroid remnant radioiodine ablation with recombinant human thyrotropin Book Section
| Authors: | Tuttle, R. M.; Robbins, R. J. |
| Editors: | Wartofsky, L.; Van Nostrand, D. |
| Article/Chapter Title: | Thyroid remnant radioiodine ablation with recombinant human thyrotropin |
| Abstract: | The primary treatment modalities for most patients with differentiated thyroid cancer include total thyroidectomy and radioactive iodine (RAI) remnant ablation (RRA; 1). The goal of RRA is to eliminate not only normal thyroid cells but also to destroy any residual microscopic thyroid carcinoma that may remain following total thyroidectomy and appropriate lymph node dissection. As reviewed in Chapters 14, 26, 32, and 88, RAI uptake into thyroid cells is enhanced by a lowiodine diet and thyrotropin (TSH) stimulation. For the past 40-50 yr, endogenous TSH production was stimulated by several weeks of thyroid hormone withdrawal prior to RAI dosing. However, thyroid hormone withdrawal often results in hypothyroid symptoms that are not well tolerated by many patients. © 2006 Humana Press Inc. |
| Book Title: | Thyroid Cancer: A Comprehensive Guide to Clinical Management. 2nd ed |
| ISBN: | 978-1-58829-462-3 |
| Publisher: | Humana Press Inc |
| Publication Place: | Totowa, NJ |
| Date Published: | 2006-01-01 |
| Start Page: | 283 |
| End Page: | 286 |
| Language: | English |
| DOI: | 10.1007/978-1-59259-995-0_27 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Book Chapter 27 -- 9781588294623 (ISBN) -- Export Date: 3 March 2014 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work